InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,259.59
(
-1.78%
)
Post# of 252501
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

swampboots

Send PM Follow Ignore
Followers 183
Posts 30024
Boards Moderated 3
Alias Born 07/09/2003

swampboots

Member Level

Re: DewDiligence post# 243137

Thursday, 07/07/2022 6:41:41 PM

Thursday, July 07, 2022 6:41:41 PM

Post# of 252501
ADVM: Google composite of their AI response to their min approach to these targets:

Adverum will no longer advance the gene therapy ADVM-022 in diabetic macular edema (DME) because of a dose-limiting toxicity, meaning the dose can not be escalated due to side effects. The biotech is forging ahead in wet age-related macular degeneration (wet AMD) but analysts have low expectations for the program.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up